Relief Therapeutics Holding AG (RLFTF)

[changes_iv]

You’ve got it badger (mc67). New eyes out there are reading...and when is our partner, Neuro Rx, going public? But, first things ($RLFTF) first!
>>>>>>>>>>>>>>>>>>>>>>>>>>>>>
Quote ~
Well you know it’s like one of those extraordinary accidents, but some people say chance favors the prepared mind. And believe it or not vasoactive intestinal peptide, which is the active ingredient we’re working with, is a neuro endocrine peptide.~ Dr. Jonathan, Neuro Rx CEO
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=158252687

Vasoactive intestinal peptide (VIP) is a basic 28 amino acid peptide that binds to a member of the class II family of G protein-coupled receptors (GPCRs). It is widely expressed throughout the body and plays an important role in numerous biological functions. VIP acts via three different GPCRs: VPAC1, VPAC2, and PAC1, which have been identified in various tissues, including brain, lung, kidney, gastrointestinal tract, tongue, and also on immunocompetent cells such as macrophages and lymphocytes. There is mounting evidence that VIP expression and signaling is altered in numerous neurological disorders, and it is becoming apparent that VIP and its receptors could be therapeutic loci for the treatment of several pathological conditions of the central nervous system. In this review, we describe the pathology of several major neurological disorders and discuss the potential pharmacotherapeutic role of VIP and its receptors for the treatment of disorders such as Alzheimer’s disease, Parkinson’s disease, and Autism Spectrum Disorders. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2967653/